EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize NRAS Mutant-Melanoma to Vemurafenib

Laura Francisca Leite do Prado-Souza, Letícia Silva Ferraz iD, Tharcísio Citrangulo Tortelli iD, César Augusto João Ribeiro iD, Danilo Trabuco do Amaral iD, Denise Costa Arruda, Érica Aparecida de Oliveira iD, Roger Chammas iD, Silvya Stuchi Maria-Engler iD, Tiago Rodrigues iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Laura Francisca Leite do Prado-Souza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Santo Andre, Sao Paulo 09210-580, Brazil. Hauptthemen laut MEDLINE: Melanoma, Vemurafenib, Mitochondria, GTP Phosphohydrolases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vemurafenib is a BRAF (rapidly accelerated fibrosarcoma B-type)-targeted therapy used to treat patients with advanced, unresectable melanoma. It inhibits the MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) pathway and tumor proliferation in BRAFV600E-mutated melanoma cells. Resistance to vemurafenib has been reported in melanoma patients due to secondary NRAS (neuroblastoma RAS viral oncogene homolog) mutations, which lead to paradoxical MAPK pathway activation and tumor proliferation. However, the impact of this paradoxical activation on mitochondrial dynamics and function in NRAS-mutated melanoma is unclear. Here, we investigated the effects of vemurafenib on NRASQ61R-mutated melanoma cells, focusing on mitochondrial dynamics and function. As expected, vemurafenib did not exhibit cytotoxicity in SK-MEL-147 NRASQ61R-mutated melanoma cells, even after 72 h of incubation. However, it significantly enhanced the MAPK/ERK signaling through paradoxical activation, accompanied by decreased expression of mitochondrial fusion proteins and activation of the fission protein DRP1 (dynamin-related protein 1), leading to small, rounded mitochondrial morphology. These observations were corroborated by transcriptome data obtained from NRAS-mutated melanoma patients, showing MFN1 (mitofusin 1) and OPA1 (optic atrophy 1) downregulation and DNM1L (DRP1 gene) upregulation. Interestingly, inhibition of mitochondrial fission with mdivi-1 or modulation of oxidative phosphorylation via respiratory chain inhibition or uncoupling significantly sensitized NRASQ61R-mutated melanoma cells to vemurafenib. Despite vemurafenib’s low cytotoxicity in NRAS-mutated melanoma, targeting mitochondrial dynamics and/or oxidative phosphorylation may offer a promising strategy for combined therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaVemurafenibMitochondriaGTP PhosphohydrolasesMembrane ProteinsMutationMAP Kinase Signaling SystemHumansCell Line, TumorMitochondrial DynamicsDynaminsMitochondrial ProteinsCell ProliferationDrug Resistance, Neoplasm

Stichwörter der Autor:innen

NRAScancermdivi-1mitochondrial dynamicsoxidative phosphorylationtargeted therapy

Substanzen

VemurafenibNRAS protein, humanGTP PhosphohydrolasesMembrane ProteinsDNM1L protein, humanDynaminsMitochondrial Proteins

Autor:innen und Institutionen

  • Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Santo Andre, Sao Paulo 09210-580, Brazil.
  • Center for Translational Research in Oncology (LIM24), Cancer Institute of the State of Sao Paulo (ICESP), Clinical Hospital of the University of Sao Paulo Medical School (HCFMUSP), Sao Paulo 01246-000, Brazil.
  • Comprehensive Center for Precision Oncology, University of São Paulo, Sao Paulo 05508-220, Brazil.
  • Integrated Biotechnology Nucleus (NIB), University of Mogi das Cruzes (UMC), Mogi das Cruzes, Sao Paulo 08780-911, Brazil.
  • Centre for Evolution and Cancer, The Institute of Cancer Research, London SM2 5NG, UK.
  • Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 05508-220, Brazil.

ORCID-Profile: Letícia Silva Ferraz, Tharcísio Citrangulo Tortelli, César Augusto João Ribeiro, Danilo Trabuco do Amaral, Érica Aparecida de Oliveira, Roger Chammas, Silvya Stuchi Maria-Engler, Tiago Rodrigues

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Prado-Souza, L. F. L. D., Ferraz, L. S., Citrangulo Tortelli, T., Ribeiro, C. A. J., Amaral, D. T. D., Arruda, D. C., Oliveira, É. A., Chammas, R., Maria-Engler, S. S., & Rodrigues, T. (2025). Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize NRAS Mutant-Melanoma to Vemurafenib. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062675

Vancouver

Prado-Souza LFLD, Ferraz LS, Citrangulo Tortelli T, Ribeiro CAJ, Amaral DTD, Arruda DC, et al. Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize NRAS Mutant-Melanoma to Vemurafenib. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062675

BibTeX
@article{PradoSouza2025,
  author = {Prado-Souza, Laura Francisca Leite do and Ferraz, Letícia Silva and Citrangulo Tortelli, Tharcísio and Ribeiro, César Augusto João and Amaral, Danilo Trabuco do and Arruda, Denise Costa and Oliveira, Érica Aparecida de and Chammas, Roger and Maria-Engler, Silvya Stuchi and Rodrigues, Tiago},
  title = {Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize NRAS Mutant-Melanoma to Vemurafenib},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062675}
}
Kostenlos starten →